Randall Pellish to Drug Costs
This is a "connection" page, showing publications Randall Pellish has written about Drug Costs.
Connection Strength
0.226
-
Cappuccio JM, Mehta N, Pellish R. Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade?) versus Biosimilar Infliximab (Renflexis?) for Acute Severe Ulcerative Colitis. Dig Dis. 2024; 42(5):496-502.
Score: 0.226